Skip to main content
Biomarker Research logoLink to Biomarker Research
. 2019 Oct 17;7:21. doi: 10.1186/s40364-019-0172-0

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia

Juanjuan Zhao 1, Yongping Song 1,, Delong Liu 1,2,
PMCID: PMC6796449  PMID: 31636908

Correction to: Biomark Res (2019) 7:19

https://doi.org/10.1186/s40364-019-0170-2

The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoxantrone, etoposide, cyclophosphamide’.

It should instead be stated that MEC stands for ‘mitoxantrone, etoposide, cytarabine’.

Contributor Information

Yongping Song, Email: songyongping@163.com.

Delong Liu, Email: DELONG_LIU@NYMC.EDU.

Reference

  • 1.Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. doi: 10.1186/s40364-019-0170-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biomarker Research are provided here courtesy of BMC

RESOURCES